Loading…
Please register to continue your trial period!
meRfi Microbiome provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.
Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.
Start your free trial and transform your understanding of the gut microbiota today!
In the context of Alogliptin & Type 2 Diabetes (T2D), the US FDA approved alogliptin on January 25, 2013, for improving glycemic control in adults with Type 2 Diabetes (T2D) as monotherapy.
The EMA granted marketing authorization for alogliptin for adults with T2D to enhance glycemic control, typically in combination with other glucose-lowering agents.
Vipidia | European Medicines Agency (EMA)
Alogliptin is well-tolerated, with a lo…